Aurobindo Pharma · NSE: AUROPHARMA · BSE: 524804

Q4 FY26 results · Jan–Mar 2026

Aurobindo Pharma reported revenue from operations of ₹8,853.34 crore (up 5.6% from Q4 FY25) and net profit of ₹920.84 crore (up 2.0% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY26	Q4 FY25	YoY	Q3 FY26	QoQ
Revenue from operations	8,853.34	8,382.12	+5.6%	8,645.90	+2.4%
Other income	117.04	134.81	−13.2%	187.64	−37.6%
Total income	8,970.38	8,516.93	+5.3%	8,833.54	+1.5%
Profit before share of associates & JVs and tax	1,293.04	1,367.28	−5.4%	1,338.15	−3.4%
Share of profit/(loss) of associates & JVs	(2.43)	(32.19)		0.37
Net profit for the period	920.84	902.83	+2.0%	909.80	+1.2%
Attributable to shareholders of the company	921.26	903.47	+2.0%	910.29	+1.2%
EPS, basic (₹)	15.86	15.56	+1.9%	15.67	+1.2%
Net margin (%)	10.4	10.8		10.5

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY26	Q4 FY25	YoY	Q3 FY26	QoQ
Revenue from operations	2,786.55	2,731.99	+2.0%	2,747.28	+1.4%
Other income	214.09	113.98	+87.8%	130.15	+64.5%
Total income	3,000.64	2,845.97	+5.4%	2,877.43	+4.3%
Profit before tax	876.31	555.52	+57.7%	781.90	+12.1%
Net profit for the period	692.23	408.17	+69.6%	582.07	+18.9%
EPS, basic (₹)	11.92	7.03	+69.6%	10.02	+19.0%
Net margin (%)	24.8	14.9		21.2

Consolidated

Filed with BSE: 21 May 2026, 22:11 IST
Board meeting: 21 May 2026
Period: 01 Jan 2026 to 31 Mar 2026
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 21 May 2026, 22:11 IST
Board meeting: 21 May 2026
Period: 01 Jan 2026 to 31 Mar 2026
Review status: Unaudited
Source: XBRL filing on BSE